Alnylam Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Alnylam Pharmaceuticals
ALNY Stock  USD 332.92  1.68  0.51%   
Alnylam Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Alnylam Pharmaceuticals' valuation are provided below:
Gross Profit
3 B
Profit Margin
0.0845
Market Capitalization
44.2 B
Enterprise Value Revenue
11.3895
Revenue
3.7 B
We have found one hundred twenty available fundamental signals for Alnylam Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Alnylam Pharmaceuticals prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 3.1 M in 2026. Enterprise Value is likely to drop to about (18.9 M) in 2026

Alnylam Pharmaceuticals Total Revenue

3.9 Billion

Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 58.4 M, Interest Expense of 265.3 M or Other Operating Expenses of 3.4 B, as well as many indicators such as Price To Sales Ratio of 13.33, Dividend Yield of 0.0 or PTB Ratio of 69.31. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Alnylam Stock
Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Alnylam Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.2 B5 B2.3 B
Slightly volatile
Other Current Liabilities1.4 B1.3 B368.7 M
Slightly volatile
Total Current Liabilities1.5 B1.5 B498.6 M
Slightly volatile
Property Plant And Equipment Net743.5 M708.1 M377.3 M
Slightly volatile
Accounts Payable121.5 M115.7 M49.7 M
Slightly volatile
Cash1.7 B1.7 B565.4 M
Slightly volatile
Non Current Assets Total961.5 M915.7 M508.2 M
Slightly volatile
Non Currrent Assets Other75.3 M81.6 M96.3 M
Very volatile
Cash And Short Term Investments3.1 B2.9 B1.5 B
Slightly volatile
Common Stock Shares Outstanding76.6 M134.7 M89.3 M
Slightly volatile
Short Term Investments684 M1.3 B859 M
Slightly volatile
Liabilities And Stockholders Equity5.2 B5 B2.3 B
Slightly volatile
Non Current Liabilities Total2.8 B2.7 B1.2 B
Slightly volatile
Other Current Assets296 M281.9 M96.1 M
Slightly volatile
Total Liabilities4.4 B4.2 B1.7 B
Slightly volatile
Property Plant And Equipment Gross1.1 B1 B432.3 M
Slightly volatile
Total Current Assets4.3 B4.1 B1.8 B
Slightly volatile
Property Plant Equipment632.1 M602 M289.1 M
Slightly volatile
Short and Long Term Debt Total645.2 M1.3 B601.2 M
Slightly volatile
Other Liabilities490.7 M467.3 M284.2 M
Slightly volatile
Current Deferred Revenue4.6 M4.8 M53.1 M
Pretty Stable
Other Stockholder Equity7.9 B7.5 B4.1 B
Slightly volatile
Short Term Debt28 M45.5 M34.4 M
Slightly volatile
Net Receivables816.4 M777.6 M208.3 M
Slightly volatile
Common Stock Total Equity770.9 K1.4 M923.1 K
Slightly volatile
Common Stock859.6 K1.3 M926.5 K
Slightly volatile
Capital Surpluse7.8 B7.4 B4.1 B
Slightly volatile
Deferred Long Term Liabilities60.8 M52.1 M67.3 M
Slightly volatile
Non Current Liabilities Other865 M1.5 B652.4 M
Slightly volatile
Deferred Long Term Asset Charges25.3 M28.5 M31.1 M
Slightly volatile
Long Term Debt Total1.2 B1.2 B448 M
Slightly volatile
Short and Long Term Debt25.6 M27 M79 M
Slightly volatile
Net Invested Capital1 B1.8 B1.5 B
Slightly volatile
Net Working Capital2 B2.6 B1.7 B
Slightly volatile
Capital Stock1.3 M1.3 M1.1 M
Slightly volatile
Capital Lease Obligations238.4 M270.6 M297.5 M
Slightly volatile

Alnylam Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization58.4 M55.7 M29.2 M
Slightly volatile
Other Operating Expenses3.4 B3.2 B1.2 B
Slightly volatile
Research Development1.4 B1.3 B581.1 M
Slightly volatile
Total Operating Expenses2.7 B2.5 B1 B
Slightly volatile
Selling General Administrative1.3 B1.2 B447.4 M
Slightly volatile
Total Revenue3.9 B3.7 B869.7 M
Slightly volatile
Gross Profit3.2 B3 B726.4 M
Slightly volatile
Cost Of Revenue711 M677.2 M261.5 M
Slightly volatile
Non Recurring176.6 M198.7 M216.9 M
Slightly volatile
Interest Income117 M111.5 M35.5 M
Slightly volatile
Reconciled Depreciation65.2 M55.7 M40.7 M
Slightly volatile
Extraordinary Items640 K720 K785.9 K
Slightly volatile

Alnylam Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation29.1 M55.7 M37.2 M
Slightly volatile
Capital Expenditures40.9 M58.7 M52.2 M
Slightly volatile
End Period Cash Flow1.7 B1.7 B566.6 M
Slightly volatile
Stock Based Compensation365.6 M348.2 M139.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.3314.026656.2234
Slightly volatile
Days Sales Outstanding72.4876.4181111
Very volatile
Stock Based Compensation To Revenue0.08910.09380.601
Slightly volatile
Capex To Depreciation1.01.05463.4652
Pretty Stable
Inventory Turnover8.68.18631.7339
Slightly volatile
Days Of Inventory On Hand42.3644.58652.7 K
Slightly volatile
Payables Turnover6.145.85171.8044
Slightly volatile
Sales General And Administrative To Revenue0.370.391.3265
Pretty Stable
Research And Ddevelopement To Revenue0.340.35666.8732
Slightly volatile
Capex To Revenue0.0150.01581.3931
Slightly volatile
Cash Per Share23.3122.201515.9236
Pretty Stable
Days Payables Outstanding59.2662.37491.2 K
Pretty Stable
Intangibles To Total Assets0.00110.00110.0074
Slightly volatile
Current Ratio2.622.76245.457
Slightly volatile
Receivables Turnover4.544.776444.8577
Slightly volatile
Graham Number14.4216.2217.6997
Slightly volatile
Capex Per Share0.670.44810.6127
Very volatile
Revenue Per Share29.7728.34987.0594
Slightly volatile
Interest Debt Per Share12.2711.68685.9356
Slightly volatile
Debt To Assets0.140.25740.183
Slightly volatile
Operating Cycle115121512
Very volatile
Days Of Payables Outstanding59.2662.37491.2 K
Pretty Stable
Ebt Per Ebit0.860.64431.1038
Pretty Stable
Quick Ratio2.572.7065.3994
Slightly volatile
Net Income Per E B T1.060.97090.9605
Slightly volatile
Cash Ratio2.241.13021.7898
Slightly volatile
Days Of Inventory Outstanding42.3644.58652.7 K
Slightly volatile
Days Of Sales Outstanding72.4876.4181111
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.020.8881.3365
Pretty Stable
Fixed Asset Turnover5.515.24522.1751
Pretty Stable
Debt Ratio0.140.25740.183
Slightly volatile
Price Sales Ratio13.3314.026656.2234
Slightly volatile
Asset Turnover0.790.74780.2444
Slightly volatile
Gross Profit Margin0.950.81770.8611
Pretty Stable

Alnylam Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.1 M5.1 M5.3 M
Very volatile

Alnylam Fundamental Market Drivers

Forward Price Earnings36.2319
Cash And Short Term Investments2.9 B

Alnylam Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.8 M4.6 M
Total Revenue3.7 B3.9 B
Cost Of Revenue677.2 M711 M
Stock Based Compensation To Revenue 0.09  0.09 
Sales General And Administrative To Revenue 0.39  0.37 
Research And Ddevelopement To Revenue 0.36  0.34 
Capex To Revenue 0.02  0.02 
Revenue Per Share 28.35  29.77 
Ebit Per Revenue 0.14  0.14 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY